$MDNAF

Medicenna Therapeutics Corp.

Medicenna Therapeutics is a Toronto-based biotechnology company developing therapies for cancer, inflammatory conditions and immune-related disorders. Its pipeline includes bizaxofusp, an IL-4-directed treatment for recurrent glioblastoma, and MDNA11, a long-acting IL-2 therapy designed to stimulate anticancer immune cells. Other candidates target autoimmune diseases and cancer, including approaches involving IL-2, IL-15, IL-4, IL-13 and PD-1.

No enriched coverage for $MDNAF in the last 7 days.

No SEC Form 4 filings for $MDNAF in the last 30 days.

See all $MDNAF insider activity →

MDNAF sentiment & insider activity

Recent MDNAF coverage spans corporate actions, technology and financial news.

What's driving MDNAF

  • Medicenna Therapeutics reported $3.7M in cash, down from $5.7M, and stated it needs additional financing to fund operations for the next 12 months. The company's quarterly net loss was $4.0M, an improvement from $4.9M in the same period last year, but financing is not guaranteed.

    tradingview.com · Nov 17, 2026

  • Medicenna reported preclinical data showing MDNA209 extended median survival 3-4x in mouse models of acute graft-versus-host disease. The drug blocked IL-2/IL-15 signaling via CD122, expanding the company's Superkine platform into autoimmune disease. Next steps include IND-enabling studies and human trials.

    tradingview.com · Oct 26, 2026

  • Medicenna Therapeutics (MDNA) will present Phase 1/2 data for MDNA11 at SITC 2026, showing activity in biomarker-enriched GI cancers, including ICI-refractory cases. The presentation highlights monotherapy and combination therapy results.

    tradingview.com · Oct 5, 2026

  • Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) announced the results of its annual general and special meeting of shareholders. All director nominees were elected with over 97% votes. Shareholders approved the re-appointment of MNP LLP as auditor and a potential share consolidation to meet U.S. exchange listing requirements. The consolidation ratio and implementation are yet to be determined.

    standard-freeholder.com · Oct 1, 2026

  • Medicenna Therapeutics shareholders approved a reverse share split, with a ratio ranging from 1-for-2 to 1-for-20, at the board's discretion. The move aims to support a potential U.S. exchange listing. The company also elected directors and re-appointed MNP LLP as auditor.

    tradingview.com · Oct 1, 2026

AlphAI scores every news story that mentions MDNAF with an AI model for sentiment and relevance, and aggregates insider trades from Medicenna Therapeutics Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MDNAF

Score

Medicenna Announces Results of Annual General and Special Meeting of Shareholders

Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) announced the results of its annual general and special meeting of shareholders. All director nominees were elected with over 97% votes. Shareholders approved the re-appointment of MNP LLP as auditor and a potential share consolidation to meet U.S. exchange listing requirements. The consolidation ratio and implementation are yet to be determined.

Related tickers